Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Tengion gets $54mm through its Series C round

Executive Summary

Tengion (regenerative medicine) has raised $33mm through the closing of its Series C venture round. New investor Deerfield Partners was joined by returning backers Bain Capital, J&J Development Corp., HealthCap, Quaker BioVentures, Oak Investment Partners, and L Capital Partners. Tengion's current lenders, Horizon Technology and Oxford Finance, also made equity investments.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies